Fulcrum Therapeutics (FULC) stock forecast for 2025
Last update: 05-12-2022, 12:52
Sector: HealthcareThe share price of Fulcrum Therapeutics, Inc. (FULC) now
What analysts predict:: $32.88
52-week high/low: $33.1 / $6.85
50/200 Day Moving Average: $15.41 / $17.85
This figure corresponds to the average price over the previous 50/200 days. For Fulcrum Therapeutics stocks, the 50-day moving average is the resistance level today.
For Fulcrum Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Fulcrum Therapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Fulcrum Therapeutics stock price in 2025. How much will one Fulcrum Therapeutics share be worth in 2025?
Is it worth taking profit / loss on Fulcrum Therapeutics stock now or waiting? What are analysts' forecasts for Fulcrum Therapeutics stock?
We forecast Fulcrum Therapeutics stock performance using neural networks based on historical data on Fulcrum Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Fulcrum Therapeutics stock prediction results are shown below and presented as a graph, table and text information.
Fulcrum Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Fulcrum Therapeutics analysts is $32.88.
Today 200 Day Moving Average is the resistance level (17.85 $).
50 Day Moving Average is the resistance level (15.41 $).
Historical and forecast chart of Fulcrum Therapeutics stock
The chart below shows the historical price of Fulcrum Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Fulcrum Therapeutics stock price can be found in the table below.
Fulcrum Therapeutics (FULC) Forecast for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 7.86 | 7.39 | 8.66 | 14.70 % |
| Feb | 7.37 | 6.27 | 8.26 | 24.11 % |
| Mar | 8.66 | 7.55 | 9.19 | 17.89 % |
| Apr | 8.10 | 7.52 | 8.49 | 11.45 % |
| May | 9.43 | 8.43 | 10.28 | 17.98 % |
| Jun | 9.09 | 8.68 | 10.15 | 14.52 % |
| Jul | 8.44 | 7.36 | 8.91 | 17.42 % |
| Aug | 9.13 | 8.11 | 10.03 | 19.13 % |
| Sep | 9.46 | 9.06 | 9.88 | 8.24 % |
| Oct | 9.42 | 8.63 | 10.38 | 16.88 % |
| Nov | 8.99 | 7.57 | 9.83 | 23.03 % |
| Dec | 8.50 | 8.03 | 9.30 | 13.71 % |
Fulcrum Therapeutics information and performance
Fulcrum Therapeutics is a biopharmaceutical company that develops drugs to treat genetic diseases. The company has developed product candidates to modulate gene expression and potentially treat the underlying cause of these diseases.
Fulcrum Therapeutics Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA, US
Market Capitalization: 312 665 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -67 074 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
DPS: N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY: N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS: -2.286
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.197
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 10.88
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 40817900
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Fulcrum Therapeutics price target for 2021 by month
Target values for the price of one Fulcrum Therapeutics share for Jan 2025.
Pessimistic target level: 7.39
Optimistic target level: 8.66
Target values for the price of one Fulcrum Therapeutics share for Feb 2025.
Pessimistic target level: 6.27
Optimistic target level: 8.26
Target values for the price of one Fulcrum Therapeutics share for Mar 2025.
Pessimistic target level: 7.55
Optimistic target level: 9.19
Target values for the price of one Fulcrum Therapeutics share for Apr 2025.
Pessimistic target level: 7.52
Optimistic target level: 8.49
Target values for the price of one Fulcrum Therapeutics share for May 2025.
Pessimistic target level: 8.43
Optimistic target level: 10.28
Target values for the price of one Fulcrum Therapeutics share for Jun 2025.
Pessimistic target level: 8.68
Optimistic target level: 10.15
Target values for the price of one Fulcrum Therapeutics share for Jul 2025.
Pessimistic target level: 7.36
Optimistic target level: 8.91
Target values for the price of one Fulcrum Therapeutics share for Aug 2025.
Pessimistic target level: 8.11
Optimistic target level: 10.03
Target values for the price of one Fulcrum Therapeutics share for Sep 2025.
Pessimistic target level: 9.06
Optimistic target level: 9.88
Target values for the price of one Fulcrum Therapeutics share for Oct 2025.
Pessimistic target level: 8.63
Optimistic target level: 10.38
Target values for the price of one Fulcrum Therapeutics share for Nov 2025.
Pessimistic target level: 7.57
Optimistic target level: 9.83
Target values for the price of one Fulcrum Therapeutics share for Dec 2025.
Pessimistic target level: 8.03
Optimistic target level: 9.30